WO2011060945A2 - Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases - Google Patents
Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases Download PDFInfo
- Publication number
- WO2011060945A2 WO2011060945A2 PCT/EP2010/007025 EP2010007025W WO2011060945A2 WO 2011060945 A2 WO2011060945 A2 WO 2011060945A2 EP 2010007025 W EP2010007025 W EP 2010007025W WO 2011060945 A2 WO2011060945 A2 WO 2011060945A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsule according
- pharmaceutical
- pharmaceutical capsule
- microcapsules
- group formed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the outer coating of the capsule contains, as well as water, a notable quantity of conventional additives such as plasticizers, colorants, opacifiers and preservatives, it is also very difficult to satisfactorily prevent or control the possible incompatibilities between these and the active ingredient.
- additives can facilitate the oxidation, degradation or hydrolysis processes, causing a loss of activity of the active ingredient formulated [EP 0769938 B1].
- Another factor to take into account is the possible chemical interaction between the content and gelatin in the capsule, which may favor cross-linking and thus reduce the capsule's solubility in the aqueous medium (delaying its speed of disintegration).
- WO 2007/103557 A2 it proposed as a solution to the problems of chemical incompatibilities in compositions with two or more active pharmaceutical ingredients, the physical separation of the components in a gelatin capsule, hard or soft, which contains a first active ingredient such as the omega-3 fatty acids, with one or more capsule coatings wherein at least one of them consists of a polymer combined with another active ingredient such as enalapril, and the coating which contains this active ingredient is isolated from the capsule and optionally from the outside by additional coatings.
- the manufacturing process is complex due to the fragility and solubility in water of the gelatin coatings and requires a rigorous control of the temperature and speed of deposition during coating.
- the polymer of the microcapsules of the pharmaceutical capsule of this invention is selected, without restriction, from the group formed by proteins, polysaccharides, polyesters, polyacrylates, polycyanoacrylates, polyethylene glycol and/or mixtures thereof.
- the polymer of the microcapsules is selected from the group formed by gelatin, albumin, alginates, carrageenans, pectins, gum arabic, chitosan, carboxymethylcellulose, ethylcellulose, hydroxypropyl methylcellulose (HPMC), nitrocellulose, cellulose' acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate-succinate, polyvinyl acetate phthalate, poly(E-caprolactone), poly(p-dioxanone), poly(5-valerolactone), poly(p-hydroxybutyrate), poly(p-hydroxybutyrate) copolymers and ⁇ -hydroxyvaler
- the polymer is formed by copolymers of methacrylic acid (Eudragit ® L and S), polymers and copolymers of lactic and glycolic acids, polymers and copolymers of lactic and glycolic acids and polyethylene glycol, and/or mixtures thereof.
- methacrylic acid Eudragit ® L and S
- polymers and copolymers of lactic and glycolic acids polymers and copolymers of lactic and glycolic acids and polyethylene glycol, and/or mixtures thereof.
- the pharmaceutical capsule of this invention can be a hard or soft capsule, of gelatin or any usual polymer in the preparation of capsules in the pharmaceutical industry, such as and not restricted to, hydroxypropyl methylcellulose (HPMC), pullulan, modified starches, carrageenans and/or mixtures thereof.
- HPMC hydroxypropyl methylcellulose
- the capsule is a gelatin capsule. More preferably, this capsule is made of soft gelatin.
- the capsule has an enteric coating.
- the capsule coating can contain other additives such as plasticizers, colorants, pigments, opacifiers, preservatives, moisturizers, surfactants, sweeteners and/or flavorings.
- the preparation of the capsule is carried out through the usual procedures in the pharmaceutical industry, and can be any form and size known by the person skilled in the art.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10781842A EP2501365A2 (en) | 2009-11-20 | 2010-11-19 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
AU2010321248A AU2010321248A1 (en) | 2009-11-20 | 2010-11-19 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
CN201080052613XA CN102711735A (en) | 2009-11-20 | 2010-11-19 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
JP2012539231A JP2013511480A (en) | 2009-11-20 | 2010-11-19 | Drug substance and polyunsaturated fatty acid ester capsules for the treatment of cardiovascular disease |
BR112012011902A BR112012011902A2 (en) | 2009-11-20 | 2010-11-19 | pharmaceutical capsule |
RU2012122886/15A RU2012122886A (en) | 2009-11-20 | 2010-11-19 | CAPSULES OF ACTIVE PHARMACEUTICAL INGREDIENTS AND COMPOUND ETHERS OF POLYUNSATURATED FATTY ACID FOR TREATMENT OF CARDIOVASCULAR DISEASES |
CA2781434A CA2781434A1 (en) | 2009-11-20 | 2010-11-19 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
MX2012005744A MX2012005744A (en) | 2009-11-20 | 2010-11-19 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases. |
IL219874A IL219874A0 (en) | 2009-11-20 | 2012-05-17 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931024A ES2364011B1 (en) | 2009-11-20 | 2009-11-20 | CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
ES200931024 | 2009-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011060945A2 true WO2011060945A2 (en) | 2011-05-26 |
WO2011060945A3 WO2011060945A3 (en) | 2012-01-19 |
Family
ID=43498490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/007025 WO2011060945A2 (en) | 2009-11-20 | 2010-11-19 | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2501365A2 (en) |
JP (1) | JP2013511480A (en) |
KR (1) | KR20120117986A (en) |
CN (1) | CN102711735A (en) |
AR (1) | AR079428A1 (en) |
AU (1) | AU2010321248A1 (en) |
BR (1) | BR112012011902A2 (en) |
CA (1) | CA2781434A1 (en) |
ES (1) | ES2364011B1 (en) |
IL (1) | IL219874A0 (en) |
MX (1) | MX2012005744A (en) |
RU (1) | RU2012122886A (en) |
TW (1) | TW201141469A (en) |
WO (1) | WO2011060945A2 (en) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012013331A3 (en) * | 2010-07-26 | 2012-06-28 | Gp-Pharm, S.A. | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases |
CN102895205A (en) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | Rapidly-dissolved azilsartan pharmaceutical preparation |
WO2014003305A1 (en) * | 2012-06-28 | 2014-01-03 | 보령제약 주식회사 | Pharmaceutical composition containing fimasartan and hydrochlorothiazide |
WO2014010896A1 (en) * | 2012-07-10 | 2014-01-16 | 보령제약 주식회사 | Pharmaceutical composition for preventing, alleviating, or treating heart failure, and complex formulations comprising same |
WO2014041445A2 (en) * | 2012-09-13 | 2014-03-20 | Mahesh Kandula | Compositions and methods for the treatment of hypertension and management of diabetic kidney disease |
FR3002735A1 (en) * | 2013-03-04 | 2014-09-05 | Virbac | ORAL NUTRITIONAL COMPOSITION AND MEDICAMENT FOR VETERINARY USE |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
CN105120845A (en) * | 2013-03-14 | 2015-12-02 | 保宁制药株式会社 | Pharmaceutical combination drug |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US10166186B2 (en) | 2013-03-04 | 2019-01-01 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US20210220253A1 (en) * | 2018-07-13 | 2021-07-22 | Biogenics, Inc. | Charcoal-Containing Double Capsule and Method for Manufacturing Same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2577685C1 (en) * | 2014-09-19 | 2016-03-20 | Александр Александрович Кролевец | Method of producing nanocapsules of potassium losartan in sodium alginate |
RU2605848C2 (en) * | 2014-10-10 | 2016-12-27 | Александр Александрович Кролевец | Method of producing nanocapsules of cephalosporin preparations in interferon |
RU2596476C1 (en) * | 2015-04-27 | 2016-09-10 | Александр Александрович Кролевец | Method of producing nanocapsules of antispasmodic medicinal plants |
JP6298435B2 (en) * | 2015-10-28 | 2018-03-20 | 大原薬品工業株式会社 | Orally disintegrating tablet containing an angiotensin II receptor antagonist |
CN106074542A (en) * | 2016-08-30 | 2016-11-09 | 佛山市弘泰药物研发有限公司 | A kind of preparation method of Azilsartan potassium salt soft capsule |
CN114617264A (en) * | 2020-12-14 | 2022-06-14 | 深圳市前海小藻科技有限公司 | Plant capsule preparation with high content of EPA |
CN116801876A (en) * | 2020-12-28 | 2023-09-22 | 株式会社丘阿德 | Pharmaceutical composition for treating chronic kidney disease |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1393805A (en) | 1971-05-24 | 1975-05-14 | Fuji Photo Film Co Ltd | Process for preparing microcapsules |
EP0052510A2 (en) | 1980-11-18 | 1982-05-26 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble polypeptides |
US4652441A (en) | 1983-11-04 | 1987-03-24 | Takeda Chemical Industries, Ltd. | Prolonged release microcapsule and its production |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
US4830853A (en) | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
GB2209937A (en) | 1987-09-21 | 1989-06-01 | Depiopharm S A | Water insoluble polypeptides |
EP0346879A1 (en) | 1988-06-15 | 1989-12-20 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
EP0264888B1 (en) | 1986-10-20 | 1991-08-07 | Warner-Lambert Company | Stabilized drug compositions |
EP0317878B1 (en) | 1987-11-24 | 1992-04-08 | Hoechst Aktiengesellschaft | Stabilized pharmaceutical agents, process for preparing them, and stable pharmaceutical preparations |
EP0468929B1 (en) | 1990-07-25 | 1994-09-28 | Sandoz Ltd. | Stabilized pharmaceutical compositions |
US5445832A (en) | 1991-07-22 | 1995-08-29 | Debio Recherche Pharmaceutique S.A. | Process for the preparation of microspheres made of a biodegradable polymeric material |
US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
EP0546358B1 (en) | 1991-11-20 | 1997-08-27 | Takeda Chemical Industries, Ltd. | Pharmaceutical compositions with angiotensin-II-antagonistic activity |
EP0769938B1 (en) | 1994-07-11 | 1998-10-28 | Therapicon Srl | A novel drug delivery system |
WO2001032689A1 (en) | 1999-11-03 | 2001-05-10 | Richter Gedeon Vegyészeti Gyár Rt. | Salts of enalapril |
EP0747050B1 (en) | 1995-06-07 | 2003-09-03 | Sanofi-Synthelabo | Pharmaceutical compositions containing irbesartan |
WO2004064809A1 (en) | 2003-01-22 | 2004-08-05 | Sandoz Ag | Solid pharmaceutical composition comprising ramipril |
WO2004064834A1 (en) | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
WO2004071526A1 (en) | 2003-02-12 | 2004-08-26 | Sigmapharm, Inc. | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
EP1083931B1 (en) | 1998-06-05 | 2005-05-11 | Warner-Lambert Company LLC | Stabilization of compositions containing ace inhibitors using magnesium oxide |
WO2005041940A1 (en) | 2003-10-30 | 2005-05-12 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
EP1429748B1 (en) | 2001-09-28 | 2005-07-20 | Bernard Charles Sherman | Solid compositions comprising ramipril |
WO2005070398A2 (en) | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
WO2005079751A2 (en) | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
WO2005084648A1 (en) | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising candesartan cilexetil |
US20050202081A1 (en) | 2002-01-15 | 2005-09-15 | Deepak Bahl | Stable pharmaceutical compositions comprising ace inhibitor(s) |
WO2006050533A2 (en) | 2004-11-05 | 2006-05-11 | King Pharmaceuticals Research & Development, Inc. | Stabilized individually coated ramipril particles, compositions and methods |
EP1674080A1 (en) | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
US20060160871A1 (en) | 2004-12-07 | 2006-07-20 | Nektar Therapeutics | Stable non-crystalline formulation comprising losartan |
WO2006081518A2 (en) | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
WO2006135415A2 (en) | 2004-09-08 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis |
EP1774967A1 (en) | 1996-06-27 | 2007-04-18 | Novartis AG | Solid oral dosage forms comprising valsartan |
US20070166372A1 (en) | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
WO2007103557A2 (en) | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US20070281000A1 (en) | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
WO2008000040A1 (en) | 2006-06-30 | 2008-01-03 | Alphapharm Pty Ltd | A stabilised composition comprising ace inhibitors |
WO2008001184A2 (en) | 2006-06-26 | 2008-01-03 | Emcure Pharmaceuticals Limited | Solid composition |
WO2008012372A1 (en) | 2006-07-28 | 2008-01-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of candesartan cilexetil form i |
US20080152717A1 (en) | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
EP1952806A1 (en) | 2007-02-01 | 2008-08-06 | Helm AG | Process for the preparation of adsorbates of candesartan |
EP1997479A1 (en) | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
EP1906931B1 (en) | 2005-06-30 | 2008-12-03 | Pharmathen S.A. | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ITMI20020731A1 (en) * | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | PHARMACEUTICAL COMPOSITIONS FOR ACETYLSALICYLIC ACID AND OMEGA-3 OILS |
ES2255426B1 (en) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA). |
WO2006102476A2 (en) * | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
US20100285121A1 (en) * | 2008-01-10 | 2010-11-11 | Takeda Pharmaceutical Company Limited | Capsule Formulation |
-
2009
- 2009-11-20 ES ES200931024A patent/ES2364011B1/en not_active Expired - Fee Related
-
2010
- 2010-11-18 AR ARP100104270A patent/AR079428A1/en unknown
- 2010-11-19 TW TW099139975A patent/TW201141469A/en unknown
- 2010-11-19 MX MX2012005744A patent/MX2012005744A/en not_active Application Discontinuation
- 2010-11-19 CN CN201080052613XA patent/CN102711735A/en active Pending
- 2010-11-19 RU RU2012122886/15A patent/RU2012122886A/en unknown
- 2010-11-19 JP JP2012539231A patent/JP2013511480A/en active Pending
- 2010-11-19 EP EP10781842A patent/EP2501365A2/en not_active Withdrawn
- 2010-11-19 AU AU2010321248A patent/AU2010321248A1/en not_active Abandoned
- 2010-11-19 KR KR1020127015768A patent/KR20120117986A/en not_active Application Discontinuation
- 2010-11-19 WO PCT/EP2010/007025 patent/WO2011060945A2/en active Application Filing
- 2010-11-19 CA CA2781434A patent/CA2781434A1/en not_active Abandoned
- 2010-11-19 BR BR112012011902A patent/BR112012011902A2/en not_active IP Right Cessation
-
2012
- 2012-05-17 IL IL219874A patent/IL219874A0/en unknown
Patent Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1393805A (en) | 1971-05-24 | 1975-05-14 | Fuji Photo Film Co Ltd | Process for preparing microcapsules |
EP0052510A2 (en) | 1980-11-18 | 1982-05-26 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble polypeptides |
US4652441A (en) | 1983-11-04 | 1987-03-24 | Takeda Chemical Industries, Ltd. | Prolonged release microcapsule and its production |
EP0264888B1 (en) | 1986-10-20 | 1991-08-07 | Warner-Lambert Company | Stabilized drug compositions |
US4830853A (en) | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
GB2209937A (en) | 1987-09-21 | 1989-06-01 | Depiopharm S A | Water insoluble polypeptides |
ES2009346A6 (en) | 1987-09-21 | 1989-09-16 | Debiopharm Sa | Sustained and controlled release of water insoluble polypeptides |
US5442008A (en) | 1987-11-24 | 1995-08-15 | Hoechst Aktiengesellschaft | Stabilized polymer film coated compounds and stabilized formulations in compressed from using same |
EP0317878B1 (en) | 1987-11-24 | 1992-04-08 | Hoechst Aktiengesellschaft | Stabilized pharmaceutical agents, process for preparing them, and stable pharmaceutical preparations |
US5151433A (en) | 1987-11-24 | 1992-09-29 | Hoechst Aktiengesellschaft | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations |
EP0346879A1 (en) | 1988-06-15 | 1989-12-20 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
EP0468929B1 (en) | 1990-07-25 | 1994-09-28 | Sandoz Ltd. | Stabilized pharmaceutical compositions |
US5445832A (en) | 1991-07-22 | 1995-08-29 | Debio Recherche Pharmaceutique S.A. | Process for the preparation of microspheres made of a biodegradable polymeric material |
EP0546358B1 (en) | 1991-11-20 | 1997-08-27 | Takeda Chemical Industries, Ltd. | Pharmaceutical compositions with angiotensin-II-antagonistic activity |
US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
EP0769938B1 (en) | 1994-07-11 | 1998-10-28 | Therapicon Srl | A novel drug delivery system |
EP0747050B1 (en) | 1995-06-07 | 2003-09-03 | Sanofi-Synthelabo | Pharmaceutical compositions containing irbesartan |
EP1774967A1 (en) | 1996-06-27 | 2007-04-18 | Novartis AG | Solid oral dosage forms comprising valsartan |
EP1083931B1 (en) | 1998-06-05 | 2005-05-11 | Warner-Lambert Company LLC | Stabilization of compositions containing ace inhibitors using magnesium oxide |
WO2001032689A1 (en) | 1999-11-03 | 2001-05-10 | Richter Gedeon Vegyészeti Gyár Rt. | Salts of enalapril |
EP1429748B1 (en) | 2001-09-28 | 2005-07-20 | Bernard Charles Sherman | Solid compositions comprising ramipril |
US20050202081A1 (en) | 2002-01-15 | 2005-09-15 | Deepak Bahl | Stable pharmaceutical compositions comprising ace inhibitor(s) |
WO2004064834A1 (en) | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
WO2004064809A1 (en) | 2003-01-22 | 2004-08-05 | Sandoz Ag | Solid pharmaceutical composition comprising ramipril |
WO2004071526A1 (en) | 2003-02-12 | 2004-08-26 | Sigmapharm, Inc. | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
WO2005041940A1 (en) | 2003-10-30 | 2005-05-12 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
WO2005079751A2 (en) | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
WO2005070398A2 (en) | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
WO2005084648A1 (en) | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising candesartan cilexetil |
WO2006135415A2 (en) | 2004-09-08 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis |
WO2006050533A2 (en) | 2004-11-05 | 2006-05-11 | King Pharmaceuticals Research & Development, Inc. | Stabilized individually coated ramipril particles, compositions and methods |
US20060160871A1 (en) | 2004-12-07 | 2006-07-20 | Nektar Therapeutics | Stable non-crystalline formulation comprising losartan |
EP1674080A1 (en) | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
WO2006081518A2 (en) | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
EP1906931B1 (en) | 2005-06-30 | 2008-12-03 | Pharmathen S.A. | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof |
US20070166372A1 (en) | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
WO2007103557A2 (en) | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US20070281000A1 (en) | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
WO2008001184A2 (en) | 2006-06-26 | 2008-01-03 | Emcure Pharmaceuticals Limited | Solid composition |
WO2008000040A1 (en) | 2006-06-30 | 2008-01-03 | Alphapharm Pty Ltd | A stabilised composition comprising ace inhibitors |
WO2008012372A1 (en) | 2006-07-28 | 2008-01-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of candesartan cilexetil form i |
US20080152717A1 (en) | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
EP1952806A1 (en) | 2007-02-01 | 2008-08-06 | Helm AG | Process for the preparation of adsorbates of candesartan |
EP1997479A1 (en) | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
Non-Patent Citations (5)
Title |
---|
BENATTI P. ET AL., J. AM. COLL. NUTR., vol. 23, 2004, pages 281 - 302 |
BUCHER H.C. ET AL., AM. J. MED., vol. 112, 2002, pages 298 - 304 |
HEINZ R., ADV. THER., vol. 26, 2009, pages 675 - 690 |
LEE J.H. ET AL., MAYO CLIN. PROC., vol. 83, 2008, pages 324 - 332 |
SEBURG R.A. ET AL., J. PHARM. BIOMED. ANAL., vol. 42, 2006, pages 411 - 422 |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012013331A3 (en) * | 2010-07-26 | 2012-06-28 | Gp-Pharm, S.A. | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
RU2613900C2 (en) * | 2012-06-28 | 2017-03-21 | Борюн Фармасьютикал Ко., Лтд. | Pharmaceutical composition comprising fimasartan and hydrochlorothiazide |
WO2014003305A1 (en) * | 2012-06-28 | 2014-01-03 | 보령제약 주식회사 | Pharmaceutical composition containing fimasartan and hydrochlorothiazide |
US9457094B2 (en) | 2012-06-28 | 2016-10-04 | Boryung Pharmaceutical Co., Ltd. | Pharmaceutical composition containing fimasartan and hydrochlorothiazide |
US9403793B2 (en) | 2012-07-03 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2014010896A1 (en) * | 2012-07-10 | 2014-01-16 | 보령제약 주식회사 | Pharmaceutical composition for preventing, alleviating, or treating heart failure, and complex formulations comprising same |
KR101391551B1 (en) * | 2012-07-10 | 2014-05-02 | 보령제약 주식회사 | Pharmaceutical composition for prevention and treatment of heart failure and combined formulation including the same |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
WO2014041445A2 (en) * | 2012-09-13 | 2014-03-20 | Mahesh Kandula | Compositions and methods for the treatment of hypertension and management of diabetic kidney disease |
WO2014041445A3 (en) * | 2012-09-13 | 2014-05-08 | Mahesh Kandula | Compounds and compositions for treatment of hypertension and management of diabetic kidney disease |
CN102895205A (en) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | Rapidly-dissolved azilsartan pharmaceutical preparation |
FR3002735A1 (en) * | 2013-03-04 | 2014-09-05 | Virbac | ORAL NUTRITIONAL COMPOSITION AND MEDICAMENT FOR VETERINARY USE |
US10166186B2 (en) | 2013-03-04 | 2019-01-01 | Virbac | Nutritional and medicinal oral composition for veterinary use |
WO2014136036A1 (en) * | 2013-03-04 | 2014-09-12 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US20160008373A1 (en) * | 2013-03-04 | 2016-01-14 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US10493032B2 (en) | 2013-03-04 | 2019-12-03 | Virbac | Nutritional and medicinal oral composition for veterinary use |
CN105120845A (en) * | 2013-03-14 | 2015-12-02 | 保宁制药株式会社 | Pharmaceutical combination drug |
US9592233B2 (en) | 2013-03-14 | 2017-03-14 | Boryung Pharmaceutical Co., Ltd. | Pharmaceutical combination drug |
US20160022679A1 (en) * | 2013-03-14 | 2016-01-28 | Boryung Pharmaceutical Co., Ltd. | Pharmaceutical combination drug |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9840472B2 (en) | 2013-12-07 | 2017-12-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9988340B2 (en) | 2014-09-29 | 2018-06-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US10343994B2 (en) | 2015-01-06 | 2019-07-09 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and pain |
US20210220253A1 (en) * | 2018-07-13 | 2021-07-22 | Biogenics, Inc. | Charcoal-Containing Double Capsule and Method for Manufacturing Same |
US11839681B2 (en) * | 2018-07-13 | 2023-12-12 | Biogenics, Inc. | Charcoal-containing double capsule and method for manufacturing same |
Also Published As
Publication number | Publication date |
---|---|
AR079428A1 (en) | 2012-01-25 |
MX2012005744A (en) | 2012-12-05 |
JP2013511480A (en) | 2013-04-04 |
ES2364011A1 (en) | 2011-08-23 |
BR112012011902A2 (en) | 2017-10-10 |
AU2010321248A1 (en) | 2012-06-07 |
CA2781434A1 (en) | 2011-05-26 |
EP2501365A2 (en) | 2012-09-26 |
IL219874A0 (en) | 2012-07-31 |
WO2011060945A3 (en) | 2012-01-19 |
CN102711735A (en) | 2012-10-03 |
ES2364011B1 (en) | 2013-01-24 |
RU2012122886A (en) | 2013-12-27 |
KR20120117986A (en) | 2012-10-25 |
TW201141469A (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2501365A2 (en) | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases | |
US11826475B2 (en) | Enteric coated multiparticulate compositions with a proteinaceous subcoat | |
EP1803440B1 (en) | Pharmaceutical formulation comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty asids (pufa) | |
DK169987B1 (en) | Orally administrable pharmaceutical composition containing as an active ingredient an acid labile compound or an alkali salt thereof, and a process for the preparation of the composition | |
CA2520660C (en) | Solid oral dosage form containing seamless microcapsules | |
WO2008084504A2 (en) | Pharmaceutical compositions of angiotensin ii receptor blockers | |
JP2002516270A (en) | Controlled release of lipoic acid | |
EP1893181A1 (en) | Oral dosage form comprising at least one active principle having a solubility that varies as a function of gastric ph conditions | |
EP1515704B1 (en) | Microcapsules for the delayed, controlled release of perindopril | |
WO2004080440A1 (en) | Process for the preparing of hardcapsule formulation containing lansoprazole | |
WO2011060943A1 (en) | Pharmaceutical formulations containing beta- blocking active ingredient capsules and polyunsaturated fatty acid esters | |
FR2882259A1 (en) | Use of a controlled release losartan oral dosage form, to decrease the inter individual gap of standard deviation of maximum concentration of the losartan, independent of administration of losartan before or after the meals | |
KR20080058041A (en) | Controlled release of indapamide using pellet-tape dosage form | |
IE20080345A1 (en) | A pharmaceutical composition | |
KR20040095521A (en) | Oral dosage form of benzimidazoline compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080052613.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10781842 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012539231 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010321248 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219874 Country of ref document: IL Ref document number: MX/A/2012/005744 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2781434 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4963/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010321248 Country of ref document: AU Date of ref document: 20101119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010781842 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127015768 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012122886 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012011902 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012011902 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120518 |